Sign in

    Jeff Hung

    Biotechnology Equity Research Analyst at Morgan Stanley

    Jeffrey Hung is a Biotechnology Equity Research Analyst at Morgan Stanley based in New York City, focusing on in-depth research and analysis within the biotechnology sector. He has evaluated and covered a range of biotech companies, delivering analyst ratings that synthesize quantitative and qualitative assessments including future growth potential, stock valuation, and economic trends. Hung began his finance career in equity research and has held various analytical roles prior to joining Morgan Stanley, where his work has informed investor decision-making. He holds professional credentials relevant to equity research and maintains registration with FINRA for research analyst activities.

    Jeff Hung's questions to INSMED (INSM) leadership

    Jeff Hung's questions to INSMED (INSM) leadership • Q4 2024

    Question

    Jeff Hung asked for a definition of the 41,000 bronchiectasis patients who have 'acted' on the company's website and inquired about the expected cadence of these patients seeking prescriptions post-launch.

    Answer

    CEO Will Lewis clarified that 'acting' means patients have visited the disease awareness website, downloaded materials, and registered for more information, providing contact details for future outreach. Regarding timing, he stated there is no direct precedent, but the high motivation observed in both patient registrations and physician surveys (90% intend to prescribe) suggests a strong initial interest at launch.

    Ask Fintool Equity Research AI

    Jeff Hung's questions to INSMED (INSM) leadership • Q3 2024

    Question

    An analyst on for Jeff Hung asked for clarification on the use of the additional $150 million from Pharmakon and inquired about the design of the upcoming TPIP Phase III study in PH-ILD.

    Answer

    CFO Sara Bonstein clarified the $150 million will be received in Q4 and, while not earmarked for a single program, ensures the high-value brensocatib launch is fully resourced. CEO Will Lewis stated that while the final TPIP Phase III design is not yet disclosed, the Phase II study showed compelling directional data on key endpoints like time to clinical worsening, fueling enthusiasm for the program.

    Ask Fintool Equity Research AI

    Jeff Hung's questions to INSMED (INSM) leadership • Q3 2024

    Question

    Lee Hung, on behalf of Jeff Hung at Morgan Stanley, asked for clarification on the use of the additional $150 million from Pharmakon and inquired about the design of the TPIP Phase III study in PH-ILD, including endpoints and the influence of Phase II results.

    Answer

    CFO Sara Bonstein clarified that the additional $150 million from Pharmakon is not earmarked for a specific program but ensures that the brensocatib launch is fully resourced. CEO Will Lewis stated that while the final TPIP Phase III design is not yet disclosed, the Phase II results were encouraging, showing compelling directional data on time to clinical worsening and 6-minute walk distance, which builds enthusiasm for the Phase III program.

    Ask Fintool Equity Research AI

    Jeff Hung's questions to Ultragenyx Pharmaceutical (RARE) leadership

    Jeff Hung's questions to Ultragenyx Pharmaceutical (RARE) leadership • Q4 2024

    Question

    Lee Hung, on behalf of Jeff Hung, asked if the Phase II data for setrusumab would have met the criteria for the Phase III second interim analysis and how baseline fracture rates compared.

    Answer

    CEO Emil Kakkis highlighted the Phase II p-value improvement from 0.04 at 6 months to 0.0014 at 14 months. He stated that the Phase II and Phase III populations are very comparable in terms of entry criteria, age, OI types, and baseline fracture requirements, making the Phase II results a reasonable model for Phase III.

    Ask Fintool Equity Research AI

    Jeff Hung's questions to NEUROCRINE BIOSCIENCES (NBIX) leadership

    Jeff Hung's questions to NEUROCRINE BIOSCIENCES (NBIX) leadership • Q4 2024

    Question

    Jeff Hung asked about the feedback from the FDA at the End-of-Phase-2 meetings for osavampator and NBI-568, specifically questioning if the agency had concerns about the lack of a dose response for NBI-568.

    Answer

    Chief Medical Officer Eiry Roberts stated that the company was very pleased with the outcomes for both meetings, receiving supportive guidance from the agency. Regarding NBI-568, she specified there was 'complete support' for advancing the 20-milligram dose into the Phase 3 program, with alignment on endpoints and the overall registration plan.

    Ask Fintool Equity Research AI

    Jeff Hung's questions to ACADIA PHARMACEUTICALS (ACAD) leadership

    Jeff Hung's questions to ACADIA PHARMACEUTICALS (ACAD) leadership • Q3 2024

    Question

    Jeff Hung of Morgan Stanley asked for an update on the ACP-204 program for Alzheimer's disease psychosis, specifically whether regulators have agreed to the master protocol and a reminder of the strategy.

    Answer

    Executive Elizabeth Thompson stated that they have not re-engaged with regulators yet regarding the Phase III portion of the master protocol and plan to do so further into the Phase II study. She noted this may mean the European Phase III startup is slightly slower but sees no overall impact on the strategy or timeline. An advantage could be starting the European Phase III with Phase II data already in hand, which helps with investigator interest.

    Ask Fintool Equity Research AI

    Jeff Hung's questions to RHYTHM PHARMACEUTICALS (RYTM) leadership

    Jeff Hung's questions to RHYTHM PHARMACEUTICALS (RYTM) leadership • Q3 22024

    Question

    Jeff Hung asked if the French real-world data showed a correlation between treatment benefit and time since surgical resection for hypothalamic obesity (HO) patients. He also inquired about the strategic goals of the Axovia partnership for Bardet-Biedl syndrome (BBS) and its potential to improve access to the U.K. patient registry.

    Answer

    Chairman, CEO and President David Meeker stated that time since resection does not appear to impact efficacy, as patients treated over a decade after injury showed benefits consistent with those in the Phase II trial. Regarding Axovia, he and EVP, Head of International Yann Mazabraud explained the partnership supports research into BBS eye findings and epidemiology, noting they already support the U.K. BBS registry.

    Ask Fintool Equity Research AI

    Jeff Hung's questions to ITCI leadership

    Jeff Hung's questions to ITCI leadership • Q3 2024

    Question

    Asked about the expected demand for the lumateperone LAI formulation and for details on upcoming data presentations from the Phase III MDD studies.

    Answer

    It is too early to predict demand for the LAI formulation, but they do not expect it to have a huge impact on the oral franchise, citing low LAI penetration in the market. They confirmed they will be presenting more detailed data from the MDD studies (501, 502, and 503) at the upcoming ACNP conference, including secondary endpoints and post-hoc analyses.

    Ask Fintool Equity Research AI

    Jeff Hung's questions to BLUE leadership

    Jeff Hung's questions to BLUE leadership • Q4 2023

    Question

    Asked about the expected ramp-up of patient collections across the 49 activated QTCs in the first half of the year and inquired about the patient start numbers required to achieve the gross profit milestone for the third tranche of the Hercules term loan.

    Answer

    The company did not provide specific guidance on a per-QTC basis but noted excitement and early enrollments across multiple centers. They declined to comment on the specific number of patient starts needed to reach the gross profit milestone for the third loan tranche, only reiterating the start-based milestones for the second tranche.

    Ask Fintool Equity Research AI

    Jeff Hung's questions to Evofem Biosciences (EVFM) leadership

    Jeff Hung's questions to Evofem Biosciences (EVFM) leadership • Q4 2021

    Question

    Jeff Hung of Morgan Stanley questioned the current refill rate for Phexxi, how this rate is factored into the 2022 net product sales guidance, and the demographic profile of women who are refilling their prescriptions compared to initial launch expectations.

    Answer

    CEO Saundra Pelletier reported a 37% refill rate in December, which was ahead of expectations for an on-demand product. She highlighted that the primary user base is women under 35, a younger demographic than perhaps initially anticipated, which represents a long-term growth opportunity. CFO Jay File added that the 2022 guidance assumes continued growth in refills driven by improved access and a post-COVID environment, rather than being based on a specific, fixed rate.

    Ask Fintool Equity Research AI

    Jeff Hung's questions to Evofem Biosciences (EVFM) leadership • Q3 2021

    Question

    Melina Santoro, on behalf of Jeff Hung from Morgan Stanley, requested more detail on the Q3 disconnect between prescription growth and net sales, asking when it might resolve. She also asked for an update on prescription refill rates.

    Answer

    CFO Jay File attributed the disconnect to the mix of patients utilizing copay assistance programs, a situation he expects to continue through Q4 2021. He stated that planned adjustments to the copay program starting in Q1 2022 will improve the gross-to-net ratio. An unidentified company representative added that while the refill rate percentage has declined due to a surge in new patients, the absolute volume of refills is growing.

    Ask Fintool Equity Research AI

    Jeff Hung's questions to Biohaven (BHVN) leadership

    Jeff Hung's questions to Biohaven (BHVN) leadership • Q3 2021

    Question

    Jeff Hung from Morgan Stanley inquired about the nature of the ex-U.S. partnership process, asking if it was competitive. He also sought an update on payer conversations regarding preventive treatment coverage for 2022.

    Answer

    CEO Dr. Vlad Coric confirmed that the partnership process was competitive and involved multiple parties, though he could not disclose further details due to confidentiality. CCO Bj Jones reported that payer discussions for 2022 are progressing "extremely well," expressing confidence in maintaining strong acute therapy coverage and securing favorable preventive coverage.

    Ask Fintool Equity Research AI